Cytotoxic T lymphocytes specific for the simian immunodeficiency virus

Immunological Reviews

Volumn 170, Issue , 1999, Pages 127-134

  Letvin, Norman L ^a   Schmitz, Jörn E ^a   Jordan, Holly L ^a   Seth, Aruna ^a   Hirsch, Vanessa M ^b   Reimann, Keith A ^a   Kuroda, Marelo J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; LIVE VACCINE; VACCINIA VACCINE;

ANIMAL MODEL; CYTOTOXIC T LYMPHOCYTE; LYMPH NODE; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; SPERM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HIV-1; HUMANS; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRUS REPLICATION;

EID: 0032860663     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01334.x     Document Type: Review

References (33)

1. 1. Hayami M, Ido E, Miura T. Survey of simian immunodeficiency virus among nonhuman primate populations. Curr Top Microbiol Immunol 1994;188:1-16.
2. 2. Ringler DJ, et al, Immunophenotypic characterization of the cutaneous exanthem of SIV-infected rhesus monkeys: apposition of degenerative Langerhans cells and cytotoxic lymphocytes during the development of acquired immunodeficiency syndrome. Am J Pathol 1987;126:199-207.
3. 3. Chalifoux LV, et al. Lymphadenopathy in macaques experimentally infected with the simian immunodeficiency virus (SIV). Am J Pathol 1987;128:104-110.
4. 4. Letvin NL, et al. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985;230:71-73.
5. 5. Letvin NL, King NW. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. JAIDS 1990;3:1023-1040.
6. 6. Lackner, AA. Pathology of simian immunodeficiency virus induced disease. Curr Top Microbiol Immunol 1994;188:35-59.
7. 7. Miller MD. Yamamoto H, Hughes AL, Watkins DI, Letvin NL. Definition of an epitope and MHC class 1 molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J Immunol 1991;147:320-329.
8. +) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol 1998;160:6067-6071.
9. + cytotoxic T lymphocytes. J Exp Med 1992;176:1739-1744.
10. + cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993;151:5096-5105.
11. 11. Yasutomi Y, et al. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 1993;150:3101-3107.
12. + cytotoxic T lymphocytes. Science 1991;252:440-443.
13. + lymphocyte response in acutely infected rhesus monkeys. J Virol 1993;67:1707-1711.
14. 14. Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol 1994;12:735-773.
15. 15. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981;126:1614-1619.
16. 16. Porgador A, Yewdell JW, Deng Y, Bennik JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class 1 complexes using monoclonal antibody. Immunity 1997;6:715-726.
17. 17. Dadaglio G, Nelson CA, Deck MB, Petzold SJ, Unanue ER. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 1997;6:727-738.
18. 18. Altman JD, et al. Phenotypic analysis of antigen specific T lymphocytes. Science 1996;274:94-96.
19. 19. Kuroda MJ, et al. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med 1998;187:1373-1381.
20. 20. Pantaleo G, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
21. 21. Kuroda MJ, et al. Comparative analysis of CTL in lymph nodes and the peripheral blood of simian immunodeficiency virus-infected rhesus monkeys. J Virol 1999;73:1573-1579.
22. + T lymphocytes of chronically infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Virol 1999;73:4508-4512.
23. 23. Kuroda MJ, et al. Emergence of CTL coincides with the clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol 1999;162:5127-5133.
24. + lymphocytes using a mouse-human chimeric monoclonal antibody. Am J Pathol 1999;154:1923-1932.
25. + lymphocytes. Science 1999;283:857-860.
26. 26. Stickl H. Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzener A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch Med Wochenschr 1974;99:2386-2392.
27. 27. Mayr A, Stickl H, Muller HK, Danner K, Singer H. The small pox vaccination strain MVA: marker, genetic structure, experience gained with the parental vaccination and behavior in organisms with a debilitated defense mechansim, Zentalbl Bakteriol 1978;167:375-390.
28. 28. Carroll M, Moss B. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: murine tumor model. Virology 1997;238:198-211.
29. 29. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851.
30. 30. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:1032-1040.
31. 31. VM Hirsch, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70:3741-3752.
32. 32. Wyatt LS, Shors ST, Murphy BR, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in animal model. Vaccine 1996;14:1451-1458.
33. 33. Seth A, et al. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by an major histocompatibility complex class I/peptide tetramer. Proc Natl Acad Sci USA 1998;95:10112-10116.